High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

In A Nutshell The small, short trial showed no serious side effects, but much larger and longer studies are needed to prove ...

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...

In power distribution systems, three-phase transformer configuration directly impacts system reliability and load management. Understanding the trade-offs between Delta and Wye connections enables ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

Much of the baseball world is preparing to congregate in Orlando, Fla., for the Winter Meetings, which kick off Monday. It’s a time for executives, agents and others to gather, and trades or free ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Mists of Pandaria Classic is launched Phase 3, the Thunder King, on December 9 at 3pm pacific time. The latest phase continues the main Mists Classic story through another concerted war effort event ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...

The biggest stories of the day delivered to your inbox.

A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% ...